scholarly journals Novel ACTG1 mutations in patients identified by massively parallel DNA sequencing cause progressive hearing loss

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Hiroki Miyajima ◽  
Hideaki Moteki ◽  
Timothy Day ◽  
Shin-ya Nishio ◽  
Takaaki Murata ◽  
...  
2015 ◽  
Vol 124 (1_suppl) ◽  
pp. 148S-157S ◽  
Author(s):  
Maiko Miyagawa ◽  
Shin-ya Nishio ◽  
Kozo Kumakawa ◽  
Shin-ichi Usami

Objectives: To elucidate the involvement of MYO6 mutations, known to be responsible for DFNA22/DFNB37, in Japanese hearing loss patients through the use of genetic analysis. Methods: Genomic variations responsible for hearing loss were identified by massively parallel DNA sequencing (MPS) of 63 target candidate genes in 1120 Japanese hearing loss patients, and the detailed clinical features for the patients with MYO6 mutations were collected and analyzed. Results: Four mutations were successfully found in 7 families exhibiting autosomal dominant inheritance. All of the patients showed progressive hearing loss, but hearing type and onset age varied. Further, none of the affected patients showed any associated symptoms, such as hypertrophic cardiomyopathy or retinitis pigmentosa. Conclusions: MPS is powerful tool for the identification of rare causative deafness gene mutations, such as MYO6. The clinical characteristics noted in the present study not only confirmed the findings of previous reports but provided important new clinical information.


PLoS ONE ◽  
2019 ◽  
Vol 14 (5) ◽  
pp. e0215932 ◽  
Author(s):  
Yoh-ichiro Iwasa ◽  
Shin-ya Nishio ◽  
Akiko Sugaya ◽  
Yuko Kataoka ◽  
Yukihiko Kanda ◽  
...  

2015 ◽  
Vol 124 (1_suppl) ◽  
pp. 158S-168S ◽  
Author(s):  
Maiko Miyagawa ◽  
Shin-ya Nishio ◽  
Mitsuru Hattori ◽  
Hideaki Moteki ◽  
Yumiko Kobayashi ◽  
...  

Objectives: Screening for MYO15A mutations was carried out using a large cohort to clarify the frequency and clinical characteristics of patients with MYO15A (DFNB3) mutations in a hearing loss population. Methods: Genetic analysis of 63 previously reported deafness genes based on massively parallel DNA sequencing (MPS) in 1120 Japanese hearing loss patients from 53 otorhinolaryngology departments was performed. Detailed clinical features of the patients with MYO15A mutations were then collected and analyzed. Results: Eleven patients from 10 families were found to have compound heterozygosity for MYO15A. Audiograms showed profound or high frequency hearing loss, with some patients showing progressive hearing loss. Age at onset was found to vary from 0 to 14 years, which seemed to be associated with the mutation. Four children underwent bilateral cochlear implantation for congenital hearing loss, with all showing good results. Conclusion: Mutations in the MYO15A gene are a notable cause of nonsyndromic hearing loss. MPS technology successfully detected mutations in relatively rare deafness genes such as MYO15A.


PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0193359 ◽  
Author(s):  
Masafumi Kobayashi ◽  
Maiko Miyagawa ◽  
Shin-ya Nishio ◽  
Hideaki Moteki ◽  
Taro Fujikawa ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-9
Author(s):  
Yu Chen ◽  
Yu Lu ◽  
Pilidong Kuyaxi ◽  
Jing Cheng ◽  
Juan Zhao ◽  
...  

We aim to identify the mutations of deafness genes using massively parallel DNA sequencing in the 12 Uyghur families. SNPscan method was used to screen against the 124 sites in the common deafness genes in probands. Subjects with SNPscan negativity were subject to massively parallel DNA sequencing for the sequencing of 97 genes known to be responsible for hearing loss. Eight families (66.7%) showed biallelic mutations in probands, including MYO15A mutation (6892C>T in J02 family, 9514C>T/7894G>T in J07 family, and 9514C>T in J16 family), MYO7A mutation (1258A>T in J03 family), TMC1 mutation (773G>A in J09 family and 1247T>G/1312G>A in J11 family), and PCDH15 mutation (4658delT in J08 and J13 families). Six novel types of mutation were identified including 6892C>T, 9514C>T/7894G>T, and 9514C>T in MYO15A gene, 1258A>T in MYO7A, 773G>A in TMC1, and 4658delT in PCDH15. The ratio of nonsense mutation and frameshift mutation was comparatively high. All these indicated that the mutation types reported in this study were rare. In conclusion, rare deafness genes were identified in the Uyghur families using massively parallel DNA sequencing, part of which were suggested to be related to the pathogenesis of the disease.


2015 ◽  
Vol 124 (1_suppl) ◽  
pp. 84S-93S ◽  
Author(s):  
Maiko Miyagawa ◽  
Shin-ya Nishio ◽  
Aya Ichinose ◽  
Satoshi Iwasaki ◽  
Takaaki Murata ◽  
...  

Objectives: ACTG1 has been reported to be a causative gene for autosomal dominant sensorineural hearing loss, DFNA20/26. In this study we sought to clarify the detailed mutational spectrum, clinical features, and genotype-phenotype correlations. Methods: Massively parallel DNA sequencing (MPS) of 63 target candidate genes was used to screen 1120 Japanese hearing loss patients. Results: MPS screening successfully identified 4 ACTG1 mutations in 5 families. The majority of patients showed high frequency–involved progressive hearing loss, with the age of onset mostly in the first or second decade. One patient received electric acoustic stimulation (EAS), which showed a good outcome. Conclusions: Target exon-sequencing using MPS was proven to be a powerful new clinical diagnostic tool for the identification of rare causative genes such as ACTG1. The present clinical findings not only confirmed those previous reports but also provided important new clinical information.


2018 ◽  
Vol 138 (10) ◽  
pp. 865-870 ◽  
Author(s):  
Yanfei Wang ◽  
Yu Lu ◽  
Jing Cheng ◽  
Lei Zhang ◽  
Dongyi Han ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Mohini Rajasagi ◽  
Sachet A. Shukla ◽  
Edward F. Fritsch ◽  
Derin B. Keskin ◽  
David DeLuca ◽  
...  

Key Points Tumor neoantigens are a promising class of immunogens based on exquisite tumor specificity and the lack of central tolerance against them. Massively parallel DNA sequencing with class I prediction enables systematic identification of tumor neoepitopes (including from CLL).


Sign in / Sign up

Export Citation Format

Share Document